Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

a strongly support further development of Virobay's spectrum-selective cathepsin inhibitors in metastatic and primary bone cancer, and that this novel therapeutic approach may be especially valuable in combination with existing anticancer approaches."

VBY-825 is a member of a series of highly potent, spectrum-selective cathepsin inhibitors with structural diversity, which is being developed by Virobay.  Increased cathepsin levels and activity have been shown to play a role in a variety of tumors, including lung and breast, and are correlated to poor patient prognosis.  The proteolytic activity of multiple cathepsins may play a role in degradation of the basement membrane and extracellular matrix allowing a loss of cell adhesion and facilitating tumor metastasis.  Cathepsin K inhibition has been shown to suppress bone resorption in women with post-menopausal osteoporosis as well as women with breast cancer by inhibiting osteoclast function.  Studies with cathepsin S inhibitors have demonstrated a reduction in the perception of pain (nociception) in animals, with no sedating effects, suggesting a role for cathepsin S in neuropathic and inflammatory pain.

About Virobay

Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases that are key mediators in a variety of diseases, including autoimmunity, neuropathic pain, liver disease, cancer, and cardiovascular disorders.  Virobay was founded upon a rich industry legacy of intensive research and development focused on the cathepsin family of cysteine proteases.  Today, Virobay possesses a trove of maturing assets, including an advancing clinical pipeline and well-characterized libraries of highly potent and selective inhibitors with drug-like pharmacokinetics consistent with the potential for oral once-daily dosing in humans.

Virobay's unique expertise in the structure
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
(Date:5/22/2013)... May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today ... Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer of ... on May 30 at 1:30 p.m. Eastern Time.  A live ... on the Investors page of the Cleveland BioLabs website at ...
(Date:5/22/2013)... Envera announced today that Michael McErlean has ... has an extensive background in cell production and served ... , Mike Matheny, President and Owner of ... join our team”. “Mike’s background is perfectly suited to ... and downstream processing equipment”, added Matheny. “Mike’s hands on ...
(Date:5/21/2013)... WEST PALM BEACH, Fla. , May 21, ... Inc. (NYSE: FCN ), the global ... and enhance their enterprise value (the "Company"), announced ... sciences focused personnel that were formerly included within ... Forensic and Litigation Consulting segment to form a ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Envera Appoints Michael McErlean Fermentation Manager 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2
... Oct. 27 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Wednesday, November 3, 2010 at 4:30 pm ...   http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ...
... Oct. 27 Regenicin, Inc. (OTC Bulletin Board: ... next-generation tissue-engineered skin substitutes to restore the qualities of ... Gervaise Gerstner to the company,s Scientific Advisory Board. Dr. ... of Dermatology at Mount Sinai Hospital in New York. ...
... ROCKVILLE, Md., Oct. 26 MacroGenics, Inc., a ... today that it has entered into a global ... to discover, develop and commercialize Dual-Affinity Re-Targeting (DART™) ... DART technology is a proprietary, bi-specific antibody platform ...
Cached Biology Technology:DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call 2Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board 2MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer 2MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer 3
(Date:5/21/2013)... Australian scientists have charted the path of insulin action ... provides a comprehensive blueprint for understanding what goes wrong ... Sean Humphrey and Professor David James from Sydney,s Garvan ... early online edition of the prestigious journal Cell ... hormone plays a very important role in the body ...
(Date:5/20/2013)... (MAY 20, 2013) University of Minnesota Medical School ... in partnership with the University,s Brain Tumor Program, have ... sheath tumors (MPNST) that allow them to discover new ... , The research was published this week in the ... Beauty transposon method, researchers in the lab of David ...
(Date:5/20/2013)... A National Science Foundation (NSF) planning grant will help ... a joint program of the University of Illinois at ... , "CARD will be devoted to research in drying ... products; forestry and paper products; chemical products; textiles; and ... of food science and human nutrition and the Illinois ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2
... The FASEB MARC Program is pleased to announce ... recipients of the 2011FASEB Postdoctoral Professional Development and ... Enrichment Award (funded by a grant from the ... of Health) was established to recognize outstanding achievement ...
... their skin cells provides protection from the damage caused by ... that melanin, which is produced by multitudes of the planet,s ... In certain microbes, in particular some organisms from near ... been linked to increased growth in the presence of ...
... (VBI) at Virginia Tech will continue and expand ... Computer as part of a new National Science ... usher in a paradigm shift in the way ... platform and relevant technologies," said Harold "Skip" Garner, ...
Cached Biology News:Recipients of the 2011 Postdoctoral Professional Development and Enrichment Award 2Melanin's 'trick' for maintaining radioprotection studied 2VBI, Convey Computer partner to deliver technology to biomedical, life sciences researchers 2
Anti-NCAPD3 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunoprecipitation, Western Blot...
... BIP-NC H-IPMIK-OH Lyophilized solid. ... LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. A ... V5 (Cat. No. 196810) that serves as ... apoptosis (~200 μM). Purity: ≥97% by ...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... flexible, fully automated microplate strip washer for 96- ... automated microplate strip washing capability, the Columbus combines ... operation. , Features ... 8, 12 or 16 channels, crosswise aspiration, overflow ...
Biology Products: